Trabectedin for recurrent grade 2 or 3 meningiomas

from Neuro-Oncology: The Podcast · host Dr. Iyad Alnahhas, Dr. Matthias Preusser

Dr. Iyad Alnahhas interviews Dr. Matthias Preusser about the recent manuscript entitled: "Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG)", published online in Neuro-Oncology in October 2021.

Episode metadata supplied by the publisher feed · Published Jan 28, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Trabectedin for recurrent grade 2 or 3 meningiomas

0:00 17:06

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Neuro-Oncology: The Podcast?

This episode is 17 minutes long.

When was this Neuro-Oncology: The Podcast episode published?

This episode was published on January 28, 2022.

Can I download this Neuro-Oncology: The Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!